Log In
Discover
Assets
Jobs
Behance
Pro
Hire Freelancers
Download on the App Store
Get it on Google Play
English
Čeština
Dansk
Deutsch
Español
Français
Italiano
Nederlands
Norsk
Polski
Português
Pусский
Suomi
Svenska
Türkçe
日本語
한국어
中文(简体)
中文(繁體)
About
Blog
TOU
Privacy
Community
Help
Do not sell or share my personal information
Sign Up
Skip to Main Content
Skip to Footer
Behance
Behance
Navigate to behance.net
Explore
Assets
Jobs
Behance
Pro
Hire Freelancers
search
magnifying glass
Sort & filter all:
Projects
Images
People
Assets
People to Hire
Cancel
search
magnifying glass
View your notifications within Behance.
View your notifications within Behance.
Log In
Sign Up
search
magnifying glass
Adobe, Inc.
Adobe, Inc.
Navigate to adobe.com
+2
Follow All
Unfollow All
Follow
Following
Tools
After Effects
XD
Sketch
Principle
Tools
Add to Moodboard
Save
Share & Embed This Project
Share
Appreciate
Appreciate
Follow All
Following All
Unfollow All
Follow All
Unfollow All
+2
Control Pharmacy
Multiple Owners
•
Follow All
Following All
Unfollow All
Join Behance
Sign up
or
Sign in
to view personalized recommendations, follow creatives, and more.
Sign Up With Email
Sign Up
or
Join Behance
Sign up
or
Sign in
to view personalized recommendations, follow creatives, and more.
Sign Up With Email
Sign Up
or
Control Pharmacy
2.2k
21.8k
50
Published:
July 6th 2021
+2
Multiple Owners
Follow All
Following All
Unfollow All
Owners
Anastasia Dianova
Netherlands
Follow
Following
Unfollow
Chipsa Design
Pro
Tbilisi, Georgia
Follow
Following
Unfollow
Alexandr Pedchenko
Tbilisi, Georgia
Follow
Following
Unfollow
Nikita Isaev
Toronto, Ontario, Canada
Follow
Following
Unfollow
Project Made For
CHIPSA
Control Pharmacy
MVP development for a California startup that is launching a new line of cannabis pills and delivery devices
2.2k
21.8k
50
Published:
July 6th 2021
Tools
After Effects
XD
Sketch
Principle
Creative Fields
Web Design
Interaction Design
UI/UX
cannabis
medical
medicine
minimal
pharmacy
typography
Copyright Info
Attribution, Non-commercial, No Derivatives
Read More
Report
